Bisoprolol-d7 (hemifumarate)
(Synonyms: 富马酸比索洛尔 d7 (hemifumarate)) 目录号 : GC46932A neuropeptide with diverse biological activities
Sample solution is provided at 25 µL, 10mM.
Bisoprolol-d7 (hemifumarate) is intended for use as an internal standard for the quantification of bisoprolol by GC- or LC-MS. Bisoprolol is a potent β-adrenergic receptor (β-AR) antagonist that is selective for β1-ARs over β2-ARs (Kis = 25 and 480 nM, respectively in S49 cells overexpressing the human receptors).1 It also selectively binds to β1-ARs over β2-ARs in human myocardium (Kis = 75.8 and 991 nM, respectively).2 Bisoprolol binds to rat ventricular myocytes and heart membrane (Kis = 20 and 38.1 nM, respectively) and to rat β1-AR in salivary glands and β2-AR in reticulocytes (Kis = 24 and 1,945 nM, respectively).3,4 In vivo, it inhibits increases in heart rate induced by isoproterenol in guinea pigs.5 Bisoprolol (0.3 mg/kg) inhibits isoproterenol-induced increases in heart rate and myocardial contractility in conscious dogs. It also decreases blood pressure and heart rate in spontaneously hypertensive rats (SHRs) when chronically administered at a dose of 7.5 mg/kg twice per day over 19 weeks. Formulations containing bisoprolol have been used in the treatment of heart failure, angina pectoris, mild to moderate hypertension, and for secondary prevention of myocardial infarction.
1.Smith, C., and Teitler, M.β-blocker selectivity at cloned human β1- and β2-adrenergic receptorsCardiovasc. Drugs Ther.13(2)123-126(1999) 2.Bundkirchen, A., Brixius, K., BÖlck, B., et al.β1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studiesEur. J. Pharmacol.460(1)19-26(2003) 3.Mauz, A.B., and Pelzer, H.β-adrenoceptor-binding studies of the cardioselective β blockers bisoprolol, H-I 42 BS, and HX-CH 44 BS to heart membranes and intact ventricular myocytes of adult rats: two β1-binding sites for bisoprololJ. Cardiovasc. Pharmacol.15(3)421-427(1990) 4.Wellstein, A., Palm, D., and Belz, G.G.Affinity and selectivity of β-adrenoceptor antagonists in vitroJ. Cardiovasc. Pharmacol.8(Suppl. 11)S36-S40(1986) 5.Haeusler, G., Schliep, H.-J., Schelling, P., et al.High β1-selectivity and favourable pharmacokinetics as the outstanding properties of bisoprololJ. Cardiovasc. Pharmacol.8(Suppl. 11)S2-S15(1986)
Cas No. | N/A | SDF | |
别名 | 富马酸比索洛尔 d7 (hemifumarate) | ||
Canonical SMILES | OC(CNC(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])COC1=CC=C(COCCOC(C)C)C=C1.OC(/C=C/C(O)=O)=O | ||
分子式 | C18H24D7NO4.1/2C4H4O4 | 分子量 | 390.5 |
溶解度 | DMSO: slightly soluble,Methanol: slightly soluble | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.5608 mL | 12.8041 mL | 25.6082 mL |
5 mM | 0.5122 mL | 2.5608 mL | 5.1216 mL |
10 mM | 0.2561 mL | 1.2804 mL | 2.5608 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet